**
Nooe Nordisk’s stock saw a rise in Friday trading after the company announced positive results from trials of its new weight-loss drug, amycretin. The drug, similar to their blockbuster drugs Wegovy and Ozempic, showed up to 22% weight loss in early-stage tests.
Amycretin was tested as an injection once weekly at doses ranging from 10mg to 20mg on 125 participants over 36 weeks. The highest dose achieved the best results. However, a pill version of the drug, which also showed similar effects, had mixed results in earlier trials last year, prompting questions about its safety.
Despite initial positive market reaction post-trial results, Novo’s stock dipped slightly after the trial results were announced due to late-stage issues with their previous product, CagriSema. The company is now focusing on further testing of amycretin in adults and awaiting results from a larger Phase III trial.
Mizuho’s healthcare expert Jared Holz expressed optimism about Novo’s pipeline, noting that if amycretin shows consistent efficacy and safety in later trials, it could become a leading obesity treatment alongside existing GLP-1 products. However, the company remains cautious due to past underperformance despite its promising initial results.
Novo executives praised the subcutaneous Phase 1b/2a trial results for amycretin, emphasizing its potential as an unimolecular GLP-1 and amylin receptor agonist, a role they had previously filled with their oral formulations. The stock remains undervalued compared to Novo’s peers in the pharma sector.
Anjalee Khemlani, senior health reporter at Yahoo Finance, will provide further insights into the latest developments affecting Novo’s stock and the broader pharma industry. For more analysis, visit [link].
Source: https://finance.yahoo.com/news/novo-nordisk-stock-pops-on-phase-i-data-for-new-weight-loss-drug-amycretin-134158777.html